Diamyd Medical increases strategic investment in the stem cell company Cellaviva
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that the Company has increased its investment in the associated company Cellaviva AB with an additional SEK 1.3 million. The investment is made within the framework of a convertible loan of SEK 2.7 million, mainly directed at existing shareholders.The convertible loan will, among others, be used to finance Cellaviva’s development of existing service offerings to include saving of stem cells from umbilical cord and for the establishment of Cellaviva’s research bank. “With this investment Diamyd Medical